Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
112 hedge funds and large institutions have $133M invested in Provention Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 22 closing their positions.
177% more call options, than puts
Call options by funds: $4.5M | Put options by funds: $1.63M
8% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 37
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
3% less funds holding
Funds holding: 115 → 112 (-3)
7% less capital invested
Capital invested by funds: $143M → $133M (-$10M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
+$10.8M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.93M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$646K |
| 4 |
DCM
DG Capital Management
New York
|
+$479K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$398K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.51M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.35M |
| 3 |
6CM
683 Capital Management
New York
|
-$1.27M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.03M |
| 5 |
SG Americas Securities
New York
|
-$945K |
PRVB Hedge Fund Activity: Q4 2021 in Review
112 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2021, worth a combined $133M — down 7% from $143M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PRVB and 20 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 34 added.
The largest buyer was Sessa Capital, adding an estimated $10.8M. The largest seller was Millennium Management, cutting an estimated $1.51M.
- 112 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2021, down from 115 in Q3 2021.
- Funds reported $133M of Provention Bio, Inc. Common Stock stock for Q4 2021, down 7% quarter-over-quarter.
- 20 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2021 and 22 closed out, a net change of -2 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q4 2021 was Sessa Capital, an estimated $10.8M added.
- The largest Provention Bio, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $1.51M sold.
Based on aggregated 13F filings for Q4 2021.